Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results, Misses Expectations By $0.12 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA) posted its earnings results on Monday. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12), Zacks reports. The company had revenue of $14.36 million during the quarter, compared to the consensus estimate of $16.22 million. Enanta Pharmaceuticals had a negative return on equity of 61.61% and a negative net margin of 96.89%.

Enanta Pharmaceuticals Trading Up 0.0%

NASDAQ ENTA traded up $0.01 on Wednesday, reaching $13.53. 17,035 shares of the stock were exchanged, compared to its average volume of 194,656. Enanta Pharmaceuticals has a one year low of $6.60 and a one year high of $17.15. The firm has a market capitalization of $393.31 million, a PE ratio of -5.61 and a beta of 0.98. The company’s 50-day simple moving average is $13.13 and its two-hundred day simple moving average is $13.44.

Institutional Trading of Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Virtu Financial LLC purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at $220,000. Invesco Ltd. boosted its holdings in Enanta Pharmaceuticals by 325.2% in the 4th quarter. Invesco Ltd. now owns 253,811 shares of the biotechnology company’s stock worth $4,003,000 after buying an additional 194,113 shares during the period. Krensavage Asset Management LLC increased its stake in Enanta Pharmaceuticals by 30.8% in the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after buying an additional 651,946 shares in the last quarter. Wellington Management Group LLP purchased a new stake in Enanta Pharmaceuticals in the 4th quarter worth $997,000. Finally, Opaleye Management Inc. bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $1,183,000. 94.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wall Street Zen cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.